55m
Bayer Aktiengesellschaft Spotlights OCEANIC-STROKE Data: Asundexian Cuts Recurrent Stroke Risk 26%
Bayer Aktiengesellschaft (ETR:BAYN) highlighted results from its OCEANIC-STROKE phase III trial during an investor webinar held at ISC 2026 in New Orleans, outlining what company executives and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results